Figure 6
From: In vitro and in vivo multidrug resistance reversal activity by a Betti-base derivative of tylosin
Effect of doxorubicin on the tumour weight in the presence or absence of TBN. Tumours consisted of transfected L5178 cells growing subcutaneously in DBA/2 mice. When the tumour size reached 0.5 cm diameter, the animals were randomised and treated every second day. The TBN (10 or 50 mg kg–1) was administered i.p. 3 h before doxorubicin (4 or 2 mg kg–1, respectively) was injected i.p. On day 12, animals were killed and tumours were excised and weighed. The values represent mean ± s.e. of five to eight animals per group. Significant differences between means, as specified by capped lines, are indicated by **P<0.001. ns, not significant.
